

CellProthera to Present ProtheraCytes® Clinical Data and Receive a Stem Cell Engineering Abstract Award for Phase I/IIb Results at ISCT 2025 Scientific Annual Meeting in New Orleans

CellProthera CSO Ibon Garitaonandia will present data from recent Phase I/IIb trial for ProtheraCytes at the conference on May 8

Mulhouse, France, April 30, 2025 – CellProthera, a regenerative cell therapy developer specializing in ischemic diseases, will be presenting two oral abstracts at International Society for Cell & Gene Therapy (ISCT) 2025 New Orleans on May 8 stemming from the recently completed Phase 1/2b EXCELLENT trial for the company's lead therapy, ProtheraCytes. The trial reported positive safety and efficacy data in patients following severe acute myocardial infarction, demonstrating the potential for ProtheraCytes to repair and regenerate heart tissue in this group.

Ibon Garitaonandia, Chief Scientific Officer at CellProthera, will present data on the study's outcomes, for which CellProthera has been named winner of the Stem Cell Engineering Abstract Award, sponsored by the ISCT Stem Cell Engineering Committee. Garitaonandia will also present data on the validation of the method used for measuring the potency of the therapy, which will be used to release clinical batches in a forthcoming Phase 3 study of ProtheraCytes®, which are expanded autologous CD34+ cells.

Details on the two oral abstracts are below.

Results of the Phase I/IIb EXCELLENT trial evaluating the safety and efficacy of transcatheter injection of expanded autologous CD34+ cells in patients with recent myocardial infarction

Abstract ID # 32

Session Type: Oral Abstract Session

Session Title: HEMATOPOIETIC STEM/PROGENITOR CELLS AND ENGINEERING

Session Chair: Maryam Pashar

Session Date/Time: Thursday May 8, 5:00-6:00 pm CT

Session Room: 210

Presentation Order: 5

Poster presentation at Poster Networking Reception 1

Wednesday, May 7th 19:00-20:30

Hematopoietic stem/progenitor cells and engineering

Validation of a potency assay for CD34+ cell-based therapy in post-acute myocardial infarction

Abstract ID # 26

Session Type: Oral Abstract Session

Session Title: REGULATORY AFFAIRS, QUALITY SYSTEMS, POLICY, ETHICS, AND PATIENT ACCESS

Session Chair: Chesrahmia Bouhs

Session Date/Time: Thursday May 8, 5:00-6:00 pm CT

Session Room: 208-209

Presentation Order: 1

Poster presentation at Poster Networking Reception 2

Thursday, May 8th 18:00-19:30

Regulatory affairs, quality systems, policy, ethics, and patient access

"We thank the ISCT Stem Cell Engineering Committee for this award, adding additional recognition of the critical data from our ProtheraCytes® Phase 1/2b trial," said Garitaonandia. "Supported by these outcomes and our ability to characterize clinical potency, we are gearing up to complete clinical development and bring this therapy to patients threatened by AMI."

ISCT 2025 will be held from May 7 to 10 at the Ernest N. Morial Convention Center in New Orleans.

About CellProthera

CellProthera is a regenerative cell therapy developer specializing in ischemic diseases, with a leading program in myocardial infarction. CellProthera has developed a unique GMP-compliant cell expansion process as well as proprietary automation technology for in vitro production of a large quantity of purified, expanded CD34+ cells. Its lead therapy ProtheraCytes®, is an autologous cell therapy targeted to regenerate various damaged tissues, including cardiac tissue. ProtheraCytes is registered as an Advanced Therapy Medicinal Product – ATMP – by the European Medicines Agency (EMA). CellProthera's proprietary technology platform comprises an automated expansion device called StemXpand® and its single use kit StemPack®. CellProthera is headquartered in Mulhouse, France.